| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-01 |
| タイトル |
|
|
タイトル |
An open-label interventional clinical study evaluating sweating function in dupilumab treatment for atopic dermatitis |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
dupilumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
atopic dermatitis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
anxiety |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sweat function |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
QSART |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Matsumoto, Mai
Koike, Yuta
Takenaka, Motoi
Murota, Hiroyuki
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Sweat plays a crucial role in maintaining skin homeostasis but is also considered a factor that exacerbates atopic dermatitis (AD). Patients with AD exhibit reduced sweat production and altered sweat composition, with impaired sweating function and psychological anxiety being implicated. However, few clinical studies with high-level evidence have investigated the effects of dupilumab treatment on sweating function and psychological anxiety. Methods: Seven patients with moderate-to-severe AD who received dupilumab treatment at Nagasaki University Hospital were evaluated at baseline, week 6, and week 24. Eczema severity was assessed using the Eczema Area and Severity Index (EASI) score and the Patients’ Oriented Eczema Measure (POEM). Sweating function was evaluated using the Quantitative Sudomotor Axon Reflex Test (QSART), and psychological anxiety was assessed using the State-Trait Anxiety Inventory (STAI). Results: EASI scores and POEM significantly improved at weeks 6 and 24. Sweat volume assessed by QSART increased at week 6 but showed a decreasing trend in some cases at week 24. Sweat latency shortened at week 6 but was prolonged again in some cases at week 24. State and trait anxiety scores of STAI decreased at week 6 but increased in some patients at week 24. Correlation analysis showed a negative correlation between sweat latency and state anxiety at baseline and a positive correlation between EASI and trait anxiety at week 6. No significant correlations were observed at week 24. Conclusion: Dupilumab improves skin symptoms in patients with AD and may temporarily enhance sweating function. It also affects psychological anxiety; however, its effects are inconsistent, suggesting individual variations in long-term changes. |
|
言語 |
en |
| 書誌情報 |
en : Journal of Cutaneous Immunology and Allergy
巻 8,
p. art. no. 14517,
発行日 2025-06-10
|
| 出版者 |
|
|
出版者 |
Frontiers Media S.A. |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2574-4593 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3389/jcia.2025.14517 |
| 権利 |
|
|
権利情報 |
© 2025 Matsumoto, Koike, Takenaka and Murota. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
The Journal of Cutaneous Immunology and Allergy, 8, art. no. 14517; 2025 |
|
言語 |
en |
JCIA8_14517.pdf (916 KB)
